InVivo names new CEO
This article was originally published in Clinica
Executive Summary
Cambridge, Massachusetts-based InVivo Therapeutics has named Mark Perrin chief executive officer – effective 6 January 2014. Upon his appointment, Mr Perrin will also become a member of the company's board of directors. Prior to joining the company – which specializes in drug delivery technologies for spinal cord injuries – Mr Perrin was president of Dennan Consulting, a biotech consulting firm. Mr Perrin replaces interim CEO Michael Astrue, who has been filling in since previous leader Francis Reynold stepped down in August due to a medical condition. Meanwhile, InVivo has also promoted Lisa Crockett to vice-president, regulatory and Kristin Neff to vice-president, clinical operations, effective 1 January 2014. The firm also recently made Steven McAllister interim CEO, making him the third person to head up its finance division in the last three months. InVivo saw its share price plunge in August after delaying its first-in-human trials of its biopolymer scaffold.